Cytosine arabinoside prodrug designed to bind plasma serum albumin for drug delivery
Tóm tắt
Rational design of anticancer prodrugs for efficient albumin binding can show distinct advantages in drug delivery in terms of high drug availability, long systemic circulation, potential targeting effect, and enhanced chemotherapy effect. In the present study, we reported a cytosine arabinoside (Ara-C) prodrug which could well formulate in solution and instantly transform into long-circulating nanocomplexes by hitchhiking blood-circulating albumin after i.v. administration. Specifically, Ara-C was conjugated with an albumin-binding maleimide derivative, the resulting Ara-C maleimide caproic acid conjugate (AM) was well formulated in aqueous solution, conferring high albumin-binding ability in vitro albumin-binding studies. Moreover, in vivo fluorescence images of sulfo-cyanine5 maleimide indirectly demonstrated that AM showed better accumulation in tumors, exhibiting superior tumor targeting ability and antitumor activity compared to Ara-C. Such a uniquely developed strategy, integrating high albumin-binding capability, has great potential to be applied in clinical cancer therapy.
Tài liệu tham khảo
Sun YB, Shi SL, Jing YK, Yin SL, Chen GL, Xu YJ, et al. Synthesis, transport and pharmacokinetics of 5′-amino acid ester prodrugs of 1-D-arabinofuranosylcytosine. Mol Pharm. 2008;6:315–25.
Liu YG, Dai QL, Wang SB, Deng QJ, Wu WG, Chen AZ. Preparation and in vitro antitumor effects of cytosine arabinoside-loaded genipin-poly-l-glutamic acid-modified bacterial magnetosomes. Int J Nanomedicine. 2015;10:1387–97.
Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, et al. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leuk Res. 2017;61:108–16.
DeAngelis LM, Kreis W, Chan K, Dantis E, Akerman S. Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chemother Pharmacol. 1992;29(3):173–7.
Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet. 2002;41(10):705–18.
Bhushan B, Khanadeev V, Khlebtsov B, Khlebtsov N, Gopinath P. Impact of albumin based approaches in nanomedicine: imaging, targeting and drug delivery. Adv Colloid Interf Sci. 2017;246:13–39.
Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171–83.
Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta. 2013;1830(12):5526–34.
Miele E, Spinelli GP, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99–105.
Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17:1263–8.
Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88:53–71.
Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3–6.
Mayr J, Heffeter P, Groza D, Galvez L, Koellensperger G, Roller A, et al. An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo. Chem Sci. 2017;8(3):2241–50.
Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2:59–64.
Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, et al. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano. 2016;10(11):9999–10012.
Chung SW, Choi JU, Lee BS, Byun J, Jeon OC, Kim SW, et al. Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor. Biomaterials. 2016;94:1–8.
Zhao D, Zhang H, Tao W, Wei W, Sun J, He Z. A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity. Biomater Sci. 2017;5(3):502–10.
Abu Ajaj K, Graeser R, Fichtner I, Kratz F. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol. 2009;64(2):413–8.
Abu Ajaj K, Graeser R, Kratz F. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin. Breast Cancer Res Treat. 2012;134(1):117–29.
Elsadek B, Graeser R, Esser N, Schafer-Obodozie C, Tsurumi C, Abu Ajaj K, et al. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP). Prostate Cancer Prostatic Dis. 2011;14(1):14–21.
Kratz F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs. 2007;16(6):855–66.
Wang G, Chen H, Zhao D, Ding D, Sun M, Kou L, et al. Combination of l-carnitine with lipophilic linkage-donating gemcitabine derivatives as intestinal novel organic cation transporter 2-targeting oral prodrugs. J Med Chem. 2017;60(6):2552–61.
Chen H, Wang G, Sun L, Zhang H, Sun M, Sun J et al. Regulating the alky chain length of fatty acid-didanosine prodrugs and evaluating its role in albumin binding. Drug Deliv Transl Res 2017
Absar S, Nahar K, Choi S, Ahsan F, Yang VC, Kwon YM. Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules. J Biomed Mater Res A. 2014;102(8):2481–90.
Mehtala JG, Kulczar C, Lavan M, Knipp G, Wei A. Cys34-PEGylated human serum albumin for drug binding and delivery. Bioconjug Chem. 2015;26(5):941–9.
Hu X, Song W, Li W, Guo C, Yu Z, Liu R. Effects of gamma-irradiation on the molecular structures and functions of human serum albumin. J Biochem Mol Toxicol. 2016;30(11):525–32.
Tian ZY, Song LN, Zhao Y, Zang FL, Zhao ZH, Chen NH, et al. Spectroscopic study on the interaction between naphthalimide-polyamine conjugates and bovine serum albumin (BSA). Molecules. 2015;20(9):16491–523.
Tao W, Zhao D, Sun M, Li M, Zhang X, He Z, et al. Enzymatic activation of double-targeted 5'-O-L-valyl-decitabine prodrug by biphenyl hydrolase-like protein and its molecular design basis. Drug Deliv Transl Res. 2017;7(2):304–11.